Janus Henderson Group PLC raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,434,314 shares of the biopharmaceutical company’s stock after buying an additional 407,304 shares during the period. Janus Henderson Group PLC owned 4.47% of Amicus Therapeutics worth $112,109,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. FMR LLC lifted its holdings in shares of Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares during the period. Redmile Group LLC lifted its holdings in shares of Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after purchasing an additional 668,080 shares during the period. Jennison Associates LLC lifted its holdings in shares of Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after purchasing an additional 838,267 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics by 5.0% during the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after purchasing an additional 430,486 shares during the period. Finally, Palo Alto Investors LLC lifted its holdings in shares of Amicus Therapeutics by 0.7% during the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock worth $79,964,000 after purchasing an additional 57,800 shares during the period.

In other Amicus Therapeutics news, SVP Daphne Quimi sold 7,000 shares of Amicus Therapeutics stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 12,206 shares of Amicus Therapeutics stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.52, for a total transaction of $165,025.12. Following the completion of the sale, the chief executive officer now directly owns 340,207 shares of the company’s stock, valued at $4,599,598.64. The disclosure for this sale can be found here. Insiders have sold 692,643 shares of company stock valued at $9,899,547 in the last three months. 3.40% of the stock is owned by insiders.

Amicus Therapeutics, Inc. (FOLD) opened at $13.00 on Thursday. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the business earned ($0.33) EPS. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis. sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Robert W. Baird reiterated an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Chardan Capital reissued a “buy” rating and set a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Finally, Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $17.81.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Shares Bought by Janus Henderson Group PLC” was published by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/amicus-therapeutics-inc-fold-shares-bought-by-janus-henderson-group-plc.html.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.